Backed by four family offices with $500 million invested, BPGbio is a leading biologyfirst AI-powered clinical stage biopharma focused on mitochondrial biology and protein homeostasis. These two areas of medicine have brought forward treatment candidates for aggressive cancers, rare disease, and age-related ailments such as sarcopenia.
The company was founded in 2009 with the mission to improve the human condition by creating more optimized drugs and holds the first patents to AI drug discovery. BPGbio’s NAi™ platform enables a shorter pathway, lower cost, with greater predictability in drug development.
Today, the company has a deep pipeline of therapeutics. Its lead mitochondrial drug BPM31510, based upon a modified naturally occurring molecule, is being studied in phase 2 clinical trials for glioblastoma multiforme and pancreatic cancer respectively.
The drug works by increasing levels of CoQ10 in cancer cells so that the normal process of energy generation in the mitochondria is restored, leading to tumor cell death. BPM31510 has also been used over the years by several patients with different diseases on a compassionate use basis and the drug helped save their lives.
The earliest patient ever treated with then highly experimental BPM31510 was a then terminal 7-year-old boy with stage 4 Ewing’s sarcoma. Using the first every version of BPM31510, he was able to recover and has remained cancer free into adulthood, now the CEO of a small AI company. BPM31510 has been granted Orphan Drug designations by the U.S. FDA, emphasizing its potential for treating these aggressive cancers.
Негізгі бет Improving Human Condition and Saving Lives: with SFO Daniel Elliott - Family Office Online Session
No video
Пікірлер